L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals
| Autor: | Hans H. Gadebusch, Judith A. Bland, George K. Abruzzo, Evemarie C. Gilfillan, Barbara Weissberger, Barbara A. Pelak, Susan K. Hadley, Robert A. Fromtling |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Male
medicine.medical_specialty Neutropenia medicine.drug_class Cephalosporin Antibiotics Enterobacter Ceftazidime Isoindoles Diabetes Mellitus Experimental Mice Pharmacokinetics Internal medicine Drug Discovery medicine Animals Pseudomonas Infections Antibacterial agent Pharmacology biology business.industry Enterobacteriaceae Infections Drug Resistance Microbial Bacterial Infections biology.organism_classification Macaca mulatta Crossover study Cephalosporins Endocrinology Female Gentamicin Gentamicins business Enterobacter cloacae Half-Life medicine.drug |
| Zdroj: | The Journal of Antibiotics. 42:815-822 |
| ISSN: | 1881-1469 0021-8820 |
| Popis: | The therapeutic activity of L-658, 310 was demonstrated in experimental bacteremias in normal, diabetic and neutropenic mice. Especially potent activity was shown against the usually difficult to control pathogens, Enterobacter cloacae and Pseudomonas aeruginosa, that were resistant to ceftazidime and/or gentamicin. Pharmacokinetic studies in mice showed a linear dose response in serum after the 20 and 50mg/kg subcutaneous dose and urinary recoveries of administered dose of about 60% in 6 hours. Excretion was mainly by glomerular filtration. In a crossover design in rhesus monkeys, the pharmacokinetics of L-658, 310 were similar to those of ceftazidime and suggest a moderately long half-life in serum of humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|